Mankind Pharma Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹1.02L Cr
- P/E
- 47.84
- ROE
- 13.14%
- PEG
- 2.81
- Price to sales
- 6.91
- Debt to equity
- 0.39
- 52W high / low
- ₹2,618 / ₹1,927
- Sales growth (5Y)
- 18.10%
- EBITDA margin
- 25.97%
- Net profit margin
- 14.29%
- Promoter holding
- 72.62%
- Sales (last year)
- ₹14,738 Cr
Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.[1]
Guidance scorecard · Q2 FY27 call
What Mankind Pharma Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ1 FY27 call
10–20%- Mankind Pharma expects progressive recovery and double-digit growth in domestic sales, with specific focus on both Chronic and Acute segments.
- Chronic portfolio is growing strongly (15.8% growth reported), with a medium-term target to increase its share from 40% to 50%.
- Acute segment has shown steady recovery, reaching growth comparable to Indian Pharmaceutical Market (IPM) at 10.9%.
- BSV (specialty business) is expected to grow in the high teens with balanced domestic and international expansion.
- New divisions such as Vistar aim to scale lesser-focused brands, adding to future growth.
- International business is also growing strongly (29% YoY growth reported).
- Volume growth has improved to 4.7% from 2.3% last fiscal year.
2 more points from Mankind Pharma Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY27 call
FlatSee what Mankind Pharma Ltd said on margins — free account, 30 seconds.
CapexQ1 FY27 call
Planned- Capex spend in Q1 FY27 was INR 198 crores, higher than INR 127 crores in Q1 FY26.
- Capex as a percentage of revenue is 4.9%, below the guidance of 6% to 7% for FY27.
- Company has enhanced the R&D biotech facility, indicating investment in biotech capabilities.
- Addition of a biotech facility as part of strategic changes.
2 more points from Mankind Pharma Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY27 call
See what Mankind Pharma Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY27 call
- Key insights related to business performance, growth guidance, and strategic initiatives are discussed, but there is no direct reference to order book status or pending orders in the material reviewed on pages 7-19.
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Mankind Pharma Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Mankind Pharma Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Mankind Pharma Ltd
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 76.50% | 74.88% | 74.87% | 74.87% | 72.71% | 72.70% | 72.67% | 72.67% | 72.66% | 72.66% | 72.63% | 72.62% |
| FIIs + | 6.74% | 9.87% | 11.58% | 12.37% | 13.34% | 12.92% | 13.07% | 12.83% | 11.34% | 10.24% | 9.45% | 9.37% |
| DIIs + | 9.78% | 11.14% | 9.94% | 9.91% | 11.05% | 11.47% | 11.50% | 11.91% | 13.26% | 14.46% | 15.39% | 15.54% |
| Public + | 6.97% | 4.10% | 3.61% | 2.86% | 2.89% | 2.89% | 2.75% | 2.57% | 2.75% | 2.63% | 2.53% | 2.46% |
| No. of Shareholders | 1,27,449 | 1,35,116 | 1,53,450 | 1,63,854 | 1,71,281 | 1,80,597 | 1,79,549 | 1,70,347 | 1,77,539 | 1,77,606 | 1,66,715 | 1,63,770 |
Financials of Mankind Pharma Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 2,708 | 2,607 | 2,422 | 2,868 | 3,061 | 3,199 | 3,079 | 3,570 | 3,697 | 3,567 | 3,443 | 4,031 | 4,338 |
| Expenses + | 2,025 | 2,000 | 1,836 | 2,196 | 2,214 | 2,383 | 2,396 | 2,724 | 2,776 | 2,648 | 2,513 | 2,974 | 3,167 |
| Operating Profit | 683 | 606 | 586 | 672 | 847 | 816 | 683 | 847 | 921 | 919 | 930 | 1,056 | 1,171 |
| OPM % | 25% | 23% | 24% | 23% | 28% | 26% | 22% | 24% | 25% | 26% | 27% | 26% | 27% |
| Other Income + | 63 | 75 | 94 | 108 | 109 | 87 | 249 | 83 | 94 | -31 | 94 | 49 | 99 |
| Interest | 9 | 9 | 9 | 11 | 7 | 221 | 191 | 171 | 170 | 157 | 142 | 110 | 105 |
| Depreciation | 96 | 110 | 100 | 103 | 100 | 187 | 231 | 219 | 222 | 223 | 223 | 226 | 236 |
| Profit before tax | 641 | 562 | 572 | 666 | 849 | 495 | 511 | 540 | 624 | 509 | 659 | 769 | 929 |
| Tax % | 20% | 18% | 17% | 18% | 22% | 22% | 17% | 18% | 17% | 19% | 15% | 25% | 23% |
| Net Profit + | 511 | 460 | 477 | 543 | 659 | 385 | 425 | 445 | 520 | 414 | 559 | 574 | 716 |
| EPS in Rs | 12.51 | 11.33 | 11.76 | 13.39 | 16.31 | 9.22 | 10.20 | 10.62 | 12.39 | 9.90 | 13.43 | 13.75 | 17.23 |
Financials of Mankind Pharma Ltd
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Sales + | 3,334 | 5,865 | 6,214 | 7,782 | 8,749 | 10,260 | 12,207 | 14,278 | 15,379 |
| Expenses + | 2,748 | 4,427 | 4,565 | 5,791 | 6,848 | 7,743 | 9,182 | 10,653 | 11,302 |
| Operating Profit | 586 | 1,438 | 1,649 | 1,991 | 1,902 | 2,517 | 3,026 | 3,625 | 4,077 |
| OPM % | 18% | 25% | 27% | 26% | 22% | 25% | 25% | 25% | 27% |
| Other Income + | 76 | 122 | 183 | 210 | 141 | 295 | 548 | 238 | 211 |
| Interest | 2 | 23 | 21 | 60 | 46 | 34 | 432 | 644 | 514 |
| Depreciation | 39 | 99 | 119 | 167 | 326 | 378 | 621 | 886 | 907 |
| Profit before tax | 621 | 1,438 | 1,692 | 1,975 | 1,671 | 2,399 | 2,521 | 2,333 | 2,867 |
| Tax % | 29% | 27% | 24% | 26% | 22% | 19% | 20% | 17% | |
| Net Profit + | 445 | 1,056 | 1,293 | 1,453 | 1,310 | 1,942 | 2,011 | 1,938 | 2,264 |
| EPS in Rs | 10.97 | 25.72 | 31.59 | 35.78 | 32.00 | 47.75 | 48.26 | 46.34 | 54.31 |
| Dividend Payout % | 0% | 0% | 24% | 0% | 0% | 0% | 0% | 2% |
Financials of Mankind Pharma Ltd
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 20 | 40 | 40 | 40 | 40 | 40 | 41 | 41 | 41 |
| Reserves | 2,035 | 3,445 | 4,682 | 6,115 | 7,395 | 9,323 | 14,291 | 16,259 | 17,541 |
| Borrowings + | 0 | 131 | 241 | 873 | 170 | 207 | 8,511 | 6,312 | 5,422 |
| Other Liabilities + | 968 | 1,449 | 1,397 | 2,080 | 2,080 | 2,313 | 4,808 | 5,143 | 5,950 |
| Total Liabilities | 3,022 | 5,065 | 6,360 | 9,108 | 9,686 | 11,883 | 27,652 | 27,755 | 28,954 |
| Fixed Assets + | 316 | 1,600 | 1,664 | 3,588 | 4,251 | 4,545 | 19,005 | 18,620 | 18,854 |
| CWIP | 47 | 317 | 372 | 701 | 550 | 282 | 826 | 1,128 | 752 |
| Investments | 959 | 829 | 1,512 | 1,109 | 1,346 | 2,568 | 2,042 | 1,985 | 1,909 |
| Other Assets + | 1,700 | 2,319 | 2,811 | 3,709 | 3,538 | 4,488 | 5,780 | 6,022 | 7,439 |
| Total Assets | 3,022 | 5,065 | 6,360 | 9,108 | 9,686 | 11,883 | 27,652 | 27,755 | 28,954 |
Financials of Mankind Pharma Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 1,070 | 1,137 | 920 | 1,813 | 2,152 | 2,413 | 3,121 | |
| Cash from Investing Activity + | -436 | -1,222 | -1,369 | -1,052 | -2,081 | -12,624 | -181 | |
| Cash from Financing Activity + | -531 | -8 | 605 | -740 | 5 | 10,233 | -2,953 | |
| Net Cash Flow | 103 | -92 | 156 | 22 | 77 | 22 | -12 | |
| Free Cash Flow | 853 | 826 | -1,423 | 987 | 1,771 | 1,895 | 2,387 | |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 97% | 96% | 71% | 112% | 103% | 98% | 102% |
Financials of Mankind Pharma Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 22 | 33 | 19 | 18 | 24 | 30 | 46 | 44 |
| Inventory Days | 166 | 175 | 243 | 265 | 188 | 180 | 219 | 193 |
| Days Payable | 71 | 145 | 137 | 162 | 126 | 90 | 119 | 121 |
| Cash Conversion Cycle | 117 | 63 | 125 | 121 | 86 | 120 | 146 | 117 |
| Working Capital Days | 56 | 30 | 32 | 24 | 39 | 53 | -28 | -40 |
| ROCE % | 37% | 32% | 22% | 26% | 17% | 14% |
Guidance history
How Mankind Pharma Ltd's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q1 FY27 call → | 10–20% | Flat | Planned | — | — |
| Q4 FY26 call → | 10–20% | Up 0–2% | Planned | — | — |
| Q3 FY26 call → | 10–20% | Flat | Planned | — | — |
| Q2 FY26 call → | 10–20% | Down 0–2% | Planned | — | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
62 out of 100 — Steady
Over the past year its share price has moved roughly in the middle of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +1.0% | 61% |
| Last 6 months | +9.9% | 67% |
| Last 3 months | −4.1% | 56% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Mankind Pharma Ltd: 0.4 × 61 + 0.4 × 67 + 0.2 × 56 = 62.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Mankind Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
- Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
- Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
- Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY